LIAT NACHSHON

Dr. LIAT NACHSHON

1. Institute of Allergy, Immunology and Pediatric Pulmonology, Shamir Medical Center, Be'er Yaakov, Israel
+1

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2017 in Allergy
Verified
Journal Article
Closed access
PDF file
AEA. Elizur
A. Elizur
MAM. Y. Appel
M. Y. Appel
LNLIAT NACHSHON
LIAT NACHSHON
MLM. B. Levy
M. B. Levy
NEN. Epstein‐Rigbi
N. Epstein‐Rigbi
MGM. R. Goldberg
M. R. Goldberg

26 April 2018 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
LNLIAT NACHSHON
LIAT NACHSHON
MGMichael R. Goldberg
Michael R. Goldberg
YKYitzhak Katz
Yitzhak Katz
MLMichael B. Levy
Michael B. Levy
AEArnon Elizur
Arnon Elizur

1 November 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
LNLIAT NACHSHON
LIAT NACHSHON
MGMichael R. Goldberg
Michael R. Goldberg
MLMichael B. Levy
Michael B. Levy
MAMichael Y. Appel
Michael Y. Appel
NENaama Epstein-Rigbi
Naama Epstein-Rigbi
AEArnon Elizur
Arnon Elizur

9 January 2022 in Allergy
Verified
Journal Article
Closed access
PDF file
AEArnon Elizur
Arnon Elizur
MAMichael Y. Appel
Michael Y. Appel
LNLIAT NACHSHON
LIAT NACHSHON
MLMichael B. Levy
Michael B. Levy
NENaama Epstein‐Rigbi
Naama Epstein‐Rigbi
MGMichael R. Goldberg
Michael R. Goldberg

29 April 2020 in Allergy
Verified
Journal Article
Closed access
PDF file
NENa'AMa Epstein‐Rigbi
Na'AMa Epstein‐Rigbi
MGMichael R. Goldberg
Michael R. Goldberg
MLMichael B. Levy
Michael B. Levy
LNLIAT NACHSHON
LIAT NACHSHON
AEArnon Elizur
Arnon Elizur

20 October 2022 in Allergy
Verified
Journal Article
Open access
NENa’ama Epstein‐Rigbi
Na’ama Epstein‐Rigbi
MLMichael B. Levy
Michael B. Levy
LNLIAT NACHSHON
LIAT NACHSHON
YKYael Koren
Yael Koren
YKYitzhak Katz
Yitzhak Katz
AEArnon Elizur
Arnon Elizur
Background: Oral immunotherapy (OIT) is an emerging method for treating food allergy in children. However, data regarding adults undergoing this process are lacking.Methods: We retrospectively analyzed the medical records of patients with food allergy aged ≥17 years who completed OIT treatment between April 2010 and December 2020 at Shamir Medical Center. Data were compared with that of children aged 4 to <11 years and adolescents aged ≥11 to 17 treated during the same time period.Results: A total of 96 adults at a median age of 22.3 years who underwent OIT for milk (n = 53), peanut (n = 18), sesame (n = 7), egg (n = 5), and tree nuts (n = 13) were analyzed and compared with 1299 children and 309 adolescents. Adults experienced more adverse reactions requiring injectable epinephrine, both during in‐clinic up‐dosing (49% vs. 15.9% and 26.5% for children and adolescents, respectively, p < 0.0001) and during home treatment (22.9% vs. 12.4%, p = 0.007 for children, and 17.5%, p = 0.23 for adolescents). Most adults (61.5%) were fully desensitized, but the rates of full desensitization were significantly lower than children (73.4%, p = 0.013). Significantly more adults (28.3%) undergoing milk OIT failed treatment than children (14.3%, p = 0.015) and adolescents (14.1%, p = 0.022), while failure rates in adults undergoing OIT for other foods were low (9.3%) and comparable with children and adolescents.Conclusions: OIT is successful in desensitizing most adults with IgE‐mediated food allergy. Adults undergoing milk OIT are at increased risk for severe reactions and for OIT failure while failure rates in adults undergoing OIT for other foods are low.